U.S. Markets closed

Big Biotech Needs Big M&A to Boost Their Beaten-Down Stocks

Josh Nathan-Kazis

The drug development pipelines of Gilead Sciences, Amgen and Biogen are running thin, and the companies might need to M&A to get going again, according to JPMorgan.